Raised FY2026 organic sales guidance to 2.5%-3%, or 3.5%-4% excluding SKU exits, after first-half momentum.
Plans to launch almost 20 new products through Q1 2028, including meaningful MedSurg launches in H1 2027.
Acera is expected to remain a double-digit growth contributor as Solventum integrates the synthetic-tissue franchise into Advanced Wound Care.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Solventum Corporation and 4,900+ companies.